Released Nov 9, 2026, after the close
10-Q filed Nov 9, 2026, 40 days after period end · 0001193125-26-453583
On November 9, 2026, MBX Biosciences, Inc. (the "Company") announced its financial results for the quarter ended September 30, 2026.
The release| Metric | Q3 2026 | Q3 2025 | Q3 2024 | Q3 2023 |
|---|---|---|---|---|
| Net Income | -$62.42M | -$21.62M | -$18.14M | -$10.16M |
| EPS Diluted | -$1.29 | -$0.63 | -$2.78 |
MBX Biosciences, Inc. · CIK 1776111 · Engraved from SEC EDGAR
| -$9.40 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
MBX Biosciences reported a net loss of $62.4 million for the three months ended September 30, 2026, compared with a net loss of $21.6 million for the same period in 2025.¶1¶2
Research and development expenses were $32.0 million and general and administrative expenses were $34.3 million for the three months ended September 30, 2026, compared with $19.3 million and $4.7 million for the same period in 2025.¶3¶4
As of September 30, 2026, cash, cash equivalents and marketable securities totaled $481.6 million, including net proceeds of $97.6 million from at-the-market common stock sales, which the Company expects to fund operations into 2029.¶5
The pivotal Phase 3 oPTimize trial of once-weekly canvuparatide is underway, with dosing of the first patient announced in August 2026 and enrollment expected to be approximately 160 adults.¶6